摘要
目的:探讨来那度胺联合小剂量地塞米松治疗骨髓瘤的效果。方法:纳入2022年7月—2024年7月广东省佛山市复星禅诚医院收治的80例骨髓瘤患者,按随机数字表法分为来那-地塞组和来那度胺组。来那度胺组使用来那度胺治疗,来那-地塞组使用来那度胺联合小剂量地塞米松治疗。对比两组疗效。结果:来那-地塞组总有效率为95.00%显著高于来那度胺组的77.50%(P<0.05)。治疗后,来那-地塞组红细胞沉降率、骨髓浆细胞比例及血清β-胶原降解产物(β-CTX)水平均低于来那度胺组(P<0.05),骨密度高于来那度胺组(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论:来那度胺联合小剂量地塞米松治疗骨髓瘤的效果理想,可改善骨代谢,且安全性较好。
Objective:To investigate the efficacy of lenalidomide combined with low-dose dexamethasone in the treatment of multiple myeloma.Methods:A total of 80 multiple myeloma patients admitted to Fosun Chancheng Hospital in Foshan,Guangdong,from July 2022 to July 2024 were enrolled and randomly divided into the Len-Dex group and the Lenalidomide group.The Lenalidomide group received lenalidomide monotherapy,while the Len-Dex group received lenalidomide combined with low-dose dexamethasone.The therapeutic effects of the two groups were compared.Results:The total response rate in the Len-Dex group(95.00%)was significantly higher than that in the Lenalidomide group(77.50%,P<0.05).After treatment,the Len-Dex group exhibited lower levels of erythrocyte sedimentation rate,bone marrow plasma cell percentage,and serum β-C-terminal telopeptide(β-CTX),as well as higher bone mineral density compared to the Lenalidomide group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Lenalidomide combined with low-dose dexamethasone demonstrates favorable efficacy in treating multiple myeloma,improves bone metabolism,and exhibits good safety.
作者
李锦裕
LI Jinyu(Department of Internal Medicine,Fosun Chancheng Hospital,Foshan 528000,China)
出处
《延边大学医学学报》
2025年第9期108-110,共3页
Journal of Medical Science Yanbian University
关键词
骨髓瘤
来那度胺
地塞米松
联合用药
Multiple myeloma
Lenalidomide
Dexamethasone
Combination therapy
